Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656258 | 1.00 | CD38 (0.37) | CD38SCN9AMAOBFPR2SCN3A | |
| SCHEMBL30656016 | 0.90 | CD38 (0.36) | CD38SCN9AMAOBOPRL1EDNRA | |
| SCHEMBL30656176 | 0.90 | CD38 (0.36) | CD38SCN9AMAOBOPRL1EDNRA | |
| SCHEMBL30656189 | 0.88 | SCN9A (0.36) | SCN9AMAOBSCN3AEDNRALIMK1 | |
| SCHEMBL30656331 | 0.87 | ALDH1A1 (0.38) | CD38MAOBOPRL1EDNRAL3MBTL1 | |
| SCHEMBL31350334 | 0.87 | CD38 (0.42) | CD38MAOBOPRL1EDNRACYP3A4 | |
| SCHEMBL30656124 | 0.86 | HPGDS (0.37) | SCN9AMAOBSCN3AEDNRAL3MBTL1 | |
| SCHEMBL30656180 | 0.86 | HPGDS (0.37) | SCN9AMAOBSCN3AEDNRAL3MBTL1 | |
| SCHEMBL30655957 | 0.86 | CD38 (0.38) | CD38MAOBOPRL1EDNRAL3MBTL1 | |
| SCHEMBL30656254 | 0.84 | SCN9A (0.52) | SCN9AMAOBSCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | claimed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | claimed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | CD38 1735/4885SCN9A 256/4885MAOB 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.